Expanded Access for IMMU-132

Status

APPROVED_FOR_MARKETING

Phases

Unknown

Study type

Expanded Access

Source

ClinicalTrials.gov

Registry ID

NCT04320693

Enrollment

Unknown

Registered

2020-03-25

Start date

Unknown

Completion date

Unknown

Last updated

2021-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Triple-Negative Breast Carcinoma

This is an expanded access program (EAP) for eligible participants designed to provide access to IMMU-132.

DRUGIMMU-132

IMMU-132 will be administered as an intravenous infusion on Days 1 and 8 of 21-day treatment cycles

Sex/Gender

ALL

Age

18 Years to No maximum

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026